VKTX · Viking Therapeutics, Inc.

The thesis

Viking Therapeutics is on schedule in obesity-drug development, but the shares have not reflected it. They closed at $25.83 on 22 October 2026, 38.7% below the 52-week high of $42.13 and well under the $35 price of the 24 September 2026 equity offering. The third-quarter report on 28 October 2026 is the next event that can change the read.

Viking said on 29 July 2026 that it expected to start oral VK2735 Phase 3 trials in the fourth quarter. It announced the SUNRISE program on 14 October 2026: SUNRISE-1 in adults with obesity and SUNRISE-2 in adults with obesity or overweight and type 2 diabetes. Each trial plans 560 adults on once-daily 27.5 mg, 35 mg or 55 mg doses or placebo for 68 weeks (Viking release via PR Newswire, 14 October 2026).

The narrative is maturing: the 22 September 2026 maintenance readout drew heavy coverage, Benzinga reported a 40% gain over two days, and the news since then has been the financing, analyst target cuts and a scheduled trial start that was already expected. The shares fell after the SUNRISE announcement, which shows the market is weighing the financing and the lack of pivotal results more heavily than the timetable.

The maintenance evidence is still early. On 22 September 2026 Viking reported that the combined every-other-week VK2735 group kept 90% of its prior weight loss over 12 weeks, against 61% for participants switched to placebo. Weight change was an exploratory endpoint in a study built for safety, tolerability and pharmacokinetics.

Bullish and bearish views on Viking Therapeutics, Inc.

The bull case on Viking Therapeutics, Inc. (VKTX), in brief: Oral Phase 3 has started. The bear case: Shares trade well below the financing price.

Bull case

• Oral Phase 3 has started. Viking announced SUNRISE-1 and SUNRISE-2 on 14 October 2026, inside its fourth-quarter guidance from 29 July 2026. Two 560-patient trials give the oral drug its own pivotal path alongside the injectable program.
• Reduced-frequency dosing retained weight loss. In Viking's 22 September 2026 release, the combined every-other-week group retained 90% of its week-21 weight loss at week 33, and the combined monthly group retained 85%.
• Injectable pivotal trials are fully enrolled. Viking said on 29 July 2026 that both VANQUISH trials had finished enrolling. A halt or failed efficacy result would overturn this.
• Analysts remain positive on the drug. UBS initiated with Buy and a $94 target on 15 October 2026, Canaccord Genuity kept Buy with a $106 target on 20 October 2026, and Truist kept Buy with an $85 target on 7 October 2026. These targets sit far above the $25.83 close.

Bear case

• Shares trade well below the financing price. Viking priced 7,857,143 common shares at $35 and $225 million of 2.00% convertible notes due 2032 on 24 September 2026, in an upsized $500 million offering. The 22 October 2026 close of $25.83 is under that price, and the shares fell 25.9% over three months.
• Targets are drifting lower. Canaccord Genuity lowered its target to $106 on 20 October 2026, and Truist cut to $85 from $87 on 7 October 2026. The cuts are small, but the direction is down while ratings stay at Buy.
• Maintenance evidence is exploratory and small. The 22 September 2026 study covered about 180 participants, with 12 in the highest-retention every-other-week arm.
• Pivotal timing is unconfirmed. The VANQUISH trials have 78-week primary endpoints, and Viking has not given a topline date. The SUNRISE trials run 68 weeks, so oral efficacy results are also well over a year away.

Price setup

The shares closed at $25.83 on 22 October 2026, according to adjusted daily closes. That is 38.7% below the 52-week high of $42.13 and 26.3% below the $35 offering price by simple comparison of the two levels. The 14-day Relative Strength Index, a momentum gauge where readings under 30 are called oversold, stood at 34.3.

The 9 October 2026 close was $28.51, so the shares have lost ground since the prior note even as the oral trial start and two Buy-rated analyst actions arrived. The $25 level in the invalidation condition is a round number under the last close and close to where the shares now trade.

Crowding evidence points to a market that has already reduced exposure rather than one that is stretched. The shares are well below their highs and not above a rising average. Retail and trader attention peaked around 22 September to 23 September 2026, when the company sold stock and convertible notes into a roughly 40% two-day gain (Benzinga, 23 September 2026). An earnings report is five sessions away.

Catalysts, next 30 days

• No other dated company event falls inside the next 30 days. The VANQUISH topline date and oral SUNRISE results have not been given.

Elapsed catalysts

• 28 October 2026 — Third-quarter 2026 results. Viking announced the date on 21 October 2026. The report shows the cash position after the September financing, the spending run-rate with four Phase 3 trials and any guidance on VANQUISH topline timing. (passed 9d ago)

What would change the view

The case breaks if a VANQUISH Phase 3 trial is halted or fails on efficacy, or if the second maintenance study contradicts the September retention signal. On price, a daily close below $25 would extend the decline that followed the 24 September 2026 offering.

The case would improve if the 28 October 2026 report shows cash covering the four Phase 3 trials without another raise, and if Viking gives a VANQUISH topline date. A sustained close back above the $35 offering price would show the market had absorbed the new shares.

What it trades with

Viking trades with other obesity-drug developers and large incumbents in the GLP-1 (glucagon-like peptide-1) class, so competitor trial results, pricing news and payer decisions can move the shares without any Viking event. As a clinical-stage company with no marketed product, it also follows small and mid-cap biotech funding conditions. The September offering shows the company raises capital when its shares rise.